What early diabetic-foot reports suggested · Review · 2015
What did early studies find about shockwave for diabetic foot ulcers?
This 2015 review gathered early studies of shockwave for diabetic foot ulcers. In the controlled trials it describes, more ulcers healed, and healed faster, with shockwave than with the comparison treatments. The best dose, and whether repeat booster sessions help, are still open questions.
Possible early help for diabetic foot ulcers- narrative review of early studies
- 2015
- years: the longest follow-up it describes
- 5
- comparison treatments: wound care alone or hyperbaric oxygen
- 2
Good to know: A narrative review: it describes studies one by one rather than combining their results.
Wang CJ, Cheng JH, Kuo YR, et al. Int J Surg, 2015 · Read the paper ↗
How this study worked
What the trials used
- Reported protocol
- Protocols varied: Moretti 100 pulses/cm² at 0.03 mJ/mm² every 72 h for three sessions; Saggini 0.037 mJ/mm²; Wang 2009 every second week for 6 weeks; no single validated wound protocol.
Who took part
Earlier studies of people with diabetic and other foot ulcers; no new patients.
Side effects
The review says the studies found no notable side effects.
All the numbers and the full appraisal
What the full paper reports.
Narrative review of diabetic and mixed foot-ulcer clinical studies; no new patient cohort or pooled analysis.
Clinical healing signals1 reported outcome
Clinical healing signals
Clinical healing signals qualitative evidence
Small controlled studies report higher healing/faster closure; uncontrolled long-term evidence cannot establish durable treatment benefit. No pooled estimate is provided.
Analysis details and source
Small controlled studies report higher healing/faster closure; uncontrolled long-term evidence cannot establish durable treatment benefit. No pooled estimate is provided.
How treatment was delivered
Protocols varied: Moretti 100 pulses/cm² at 0.03 mJ/mm² every 72 h for three sessions; Saggini 0.037 mJ/mm²; Wang 2009 every second week for 6 weeks; no single validated wound protocol.
The review says the cited studies reported no noteworthy side effects (Schaden et al. observed no adverse effect) but gives no harms counts, denominators or systematic surveillance.
No reproducible search, selection criteria or formal bias assessment. Strong superiority and cost-effectiveness language exceeds the narrative evidence. It mixes nonrandomized cohorts with randomized trials. Funding and conflicts declared none in this review.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- No reproducible search, selection criteria or formal bias assessment. Strong superiority and cost-effectiveness language exceeds the narrative evidence. It mixes nonrandomized cohorts with randomized trials. Funding and conflicts declared none in this review.
Source-linked critical reading
Narrative review
Technical source record
Full 3-page narrative review read: highlights, abstract, Sections 1–5 (introduction, diabetic and non-diabetic ulcers, ESWT versus hyperbaric oxygen, long-term outcomes, conclusion), declarations and references. The review has no methods section, tables or figures; no supplements.
Early studies looked promising, but this review cannot establish the best dose or whether repeated booster treatment helps.
What does this 2015 narrative review report about shockwave therapy for diabetic foot ulcers, and how well do the cited studies support its clinical claims?
Narrative clinical review of selected wound studies. It supplies no reproducible search strategy, selection flow, formal bias assessment or pooled estimate, and contributes no new patient cohort.
Narrative review of diabetic and mixed foot-ulcer clinical studies; no new patient cohort or pooled analysis.
Regimens differed between the cited studies: mostly 100 impulses/cm² (Wang 2009: 300 + 100/cm²; the long-term study: treatment area in cm² × 8, at least 500 impulses) at 0.03–0.11 mJ/mm², given from every 72 hours to every second week, or twice a week for six treatments. The review does not say whether the devices were focused.
Standard wound care, HBOT, and uncontrolled cohorts; comparisons belong to their original studies.
The cited reports assess complete ulcer closure, time to healing, perfusion, histologic or molecular markers, and late wound outcomes. Their populations, comparators and follow-up windows differ; no common prespecified review outcome or meta-analysis is provided.
Moretti is summarized as 53.33% versus 33.33% closure; Omar as 54% versus 28.5% at 20 weeks and 64.5±8.06 versus 81.17±4.35 days among healed ulcers. The 2011 HBOT comparison reports 57% versus 25%. In the long-term study, complete healing was 55.6% at 1 year and 57.4% at 5 years (48% and 43% with diabetes, 66% and 71% without), while perfusion rose for a year and then fell between years 1 and 5.
The review says the cited studies reported no noteworthy side effects (Schaden et al. observed no adverse effect) but gives no harms counts, denominators or systematic surveillance.
No reproducible search, selection criteria or formal bias assessment. Strong superiority and cost-effectiveness language exceeds the narrative evidence. It mixes nonrandomized cohorts with randomized trials. Funding and conflicts declared none in this review.
Useful historical overview, not an independent estimate of benefit or evidence for booster sessions.
An updated systematic review should search reproducibly, assess trial bias, separate ulcer etiologies and comparators, and evaluate long-term benefit and booster schedules only from controlled evidence.
Read the original article.
Extracorporeal shockwave therapy in diabetic foot ulcers
Wang CJ, Cheng JH, Kuo YR, Schaden W, Mittermayr R. · Int J Surg · 2015
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →